Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus DIUPRES 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus DIUPRES 500.
ALDORIL 15 vs DIUPRES-500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination